For the past decade, Japan’s universities have been working with venture capital to commercialize their research. Recent developments in the public and private sectors suggest this relationship is evolving
La Renon, an Indian developer and manufacturer of pharmaceutical drugs and services, has raised INR1 billion ($16 million) in Series A funding from Sequoia Capital.
Neil Shen, managing partner at Sequoia Capital China, is supporting take-private bids for budget hotel operator Home Inns and online real estate agency E-House as a growing number of US-listed Chinese companies turn their attention to domestic listings.
Warburg Pincus has raised $241.5 million by reducing its stake in US-listed biopharmaceutical developer China Biologic Products.
Panasonic Healthcare, the Japanese medical equipment manufacturer in which KKR acquired a majority stake last year, has agreed to buy Bayer’s diabetes care business for EUR1.02 billion ($1.15 billion).
Hong Kong-based pharmaceutical developer Luqa Pharma has raised a $15 million Series A round of funding led by Morningside Ventures.
Quadria Capital, the Singapore and India-based private equity firm, has reached a final close on its maiden healthcare fund at $304 million.
CITIC Private Equity has made a partial exit from Chinese biotech player 3SBio as the company raised HK$5.51 billion ($711 million), two years after leaving NASDAQ in a take-private deal.
Fidelity Growth Partners India (FGPI) and affiliated US fund Fidelity Biosciences have invested $10 million in Medwell Ventures, operator of Nightingales specialty home healthcare services.
A consortium of Chinese investors including Shanghai Fosun Pharmaceutical Group, Hopu Investments, CEL Healthcare Fund and WuXi PharmaTech will acquire Ambrx, a US-based biotech pharmaceutical developer.
Hony Capital CEO John Zhao expects to see more control opportunities arising from domestic succession planning, cross-border expansion and restructuring. He explains how his firm is preparing the ground
Private equity investors see huge opportunities in China’s hospital space on the back of healthcare reforms. But valuations are high, doctors are in limited supply, and regulation can be a headache
BeiGene, a Chinese company that develops drugs to combat cancer, has raised RMB600 million ($97 million) in a funding round led by existing investors Hillhouse Capital and an undisclosed US-based life sciences-focused public investment fund.
Taiwan-based biopharmaceutical company JHL Biotech has raised a $45 million Series C round, led by an unnamed investor. Existing backer Milestone Capital also participated, along with newcomers Sungent BioVenture and Liwick Investment Management.
CLSA Capital Partners (CLSA CP) has invested RMB150 million ($24.5 million) in Coco Healthcare Products, a Chinese manufacturer of diapers for adults and babies. It plans to help the company boost its export business.
South Korea-based Posco Capital and biopharmaceutical player Green Cross have led a $7.5 million round for Juventas Therapeutics, a clinical-stage biotech development company based in the US.
Inner Mongolia FuRui Medical Science (FuRui) started out two decades ago as a pure-play drug manufacturer, but then it found its niche developing diagnostic equipment and treatment for liver disease. Looking to bring in overseas technology, it acquired...
WuXi PharmaTech, a China-based provider of contract R&D services to the global pharmaceutical sector, has received a take-private bid led by its founder and chairman and healthcare-focused PE firm Ally Bridge Group.
India's Fortis Healthcare will sell its Singapore-based diagnostics arm RadLink-Asia to Fullerton Healthcare Group for S$111 million ($83.5 million).
Cathay Capital has led a EUR30 million ($33 million) round of funding for Echosens, a France-based diagnostic medical device manufacturer owned by China’s Inner Mongolia FuRui Medical Science.
Yunfeng Capital, Shenzhen Cowin Capital, New Horizon Capital and Hunan Haijie Healthcare Investment have provided RMB200 million ($32 million) in Series B funding for Huakang Mobile Healthcare, a Chinese mobile healthcare app developer.
China Cord Blood, a US-listed blood banking operator in which KKR holds a minority stake, has received a take-private offer from its largest shareholder, Chinese healthcare company Golden Meditech.
With A$78 billion ($61 billion) in assets, AustralianSuper is said to struggle to make fund commitments of less than A$150 million. Yet it is one of several superannuation funds backing Brandon Capital’s latest life sciences VC vehicle, which has closed...
China's Fosun International and Tencent Holdings have led a $35 million Series B round for Scanadu, a US-based medical technology start-up working on devices that can send diagnostic tests directly to smart phones.